Clinical Considerations for Immuno-oncology (IO) Sequencing in Advanced Endometrial Cancer - Episode 11
Unmet Needs and Gaps in Treatment Options for Advanced EC Post-IO Therapy
Panelists discuss how gaps in treatment options for advanced endometrial cancer (EC) following immuno-oncology (IO) therapy, including a lack of effective post-IO therapies, limited understanding of optimal sequencing, and the need for targeted therapies and improved biomarkers, highlight the ongoing challenges in personalizing treatment and managing adverse effects in this patient population.
Summary for Physicians:
There are several gaps in treatment options for patients with advanced EC following IO therapy. One major challenge is the lack of effective post-IO therapies for patients who either do not respond to initial IO treatment or experience disease progression after IO therapy. Additionally, there is limited understanding of the optimal sequencing of therapies after IO, making it difficult to select the most effective next-line treatment. Many patients also face a lack of targeted therapies for specific molecular subtypes of advanced EC, which could lead to more personalized and effective treatment approaches. Furthermore, there is an ongoing need for improved biomarkers to predict response to post-IO therapies, as well as better strategies for managing adverse effects and treatment-related complications in this patient population.
Related Content:
